![[HTML version]](/e/graphics/htmlborder.gif)
![[PDF version]](/e/graphics/pdfborder.gif)
![[CIF]](/e/graphics/cifborder.gif)
![[3d view]](/e/graphics/3dviewborder.gif)
![[Structure Factors]](/e/graphics/structurefactorsborder.gif)
![[CIF check Report]](/e/graphics/checkcifborder.gif)
![[Buy article online]](/logos/buy.gif)
![[Contents scheme]](ci6259contents.gif)
Acta Cryst. (2003). E59, o1471-o1473 [ doi:10.1107/S1600536803019470 ]
Abstract: The flunixin-meglumine complex [(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxy-N-methyl-1-hexanaminium 2-[2-methyl-3-(trifluoromethyl)anilino]nicotinate], C7H18NO5+·C14H10F3N2O2-, is a non-steroidal anti-inflammatory drug (NSAID) and a non-narcotic analgesic drug with antipyretic activities. In its crystal structure, the meglumine cations are linked through O-H
O and N-H
O hydrogen bonds to form layers parallel to the ab plane. The flunixin anions are arranged between the two cationic layers and are linked to the cations through O-H
O hydrogen bonds.
Online 11 September 2003
Copyright © International Union of Crystallography
IUCr Webmaster